研究领域

1、生物药物及疫苗生产关键技术的研究：重组蛋白的高表达调控，大规模细胞培养工艺，分离纯化工艺，生物药物质量研究

2、细胞工程研究：细胞株工程，特殊细胞的培养和临床应用

3、抗体工程研究：临床治疗用抗体的改造

4、创新生物药物的研发

项目

1. 治疗用单抗药物生产工艺优化，及临床I期试验研究.

2. 趋化因子CXCL9 抗体促进化疗后骨髓修复的药效学及其调控造血的分子机理研究.

3. Notch 1活性的快速检测试剂盒研发及其与T淋巴细胞白血病疾病进展相关性的研究.

4. 与国际国内大学、研究机构、企业开展合作研究及人才培养.

专利

1. B.Ma, D. Nellis, J. Zhu, D. Wood;Revisable Regulation of Intein Activity through Engineered New Zinc Binding Domain.;

2. Han W, Lu L, Xiang D;Methods for Protecting and Regenerating bone marrow using CXCR3 agonists and antagonists.;专利号：7,943,131 B2.

3. 王贵荣, 张宝红, 齐念民;虹吸式间歇喷雾生物反应器;专利号：ZL 2009 1 0045064.2.

4. 王贵荣, 齐念民, 张宝红, 闫继红, 廖凯;植物细胞搅拌式生物反应器连续灌注培养装置;专利号：ZL 2007 1 0044224.2.

5. 王贵荣, 齐念民, 张宝红, 闫继红, 廖凯;药用植物组织细胞连续灌注培养气升式生物反应器系统;专利号：ZL 2007 1 0044223.8.

论文

1. Update on production Recombinant Therapeutic protein Transient Gene Expression.Jianwei Zhu.Smithers iSmithers出版社, Shropshire, UK.,2013.

2. Purification of clinical-grade disulfide stabilized antibody fragment ariable-Pseudomonas exotoxin conjugate (dsFv-PE38) expressed in italic Escherichia coli.Jiang H, Xie Y, Burnette A, Roach J, Giardina SL, Hecht TT, Creekmore SP, Mitra G, Zhu J.Appl Microbiol Biotechnol.

3. Mammalian cell protein expression for biopharmaceutical production.Zhu J.Biotechnol Adv.

4. Clinical manufacturing of recombinant human interleukin 15. I. Production cell line development and protein expression in E. coli with stop codon optimization.Vyas VV, Esposito D, Sumpter TL, Broadt TL, Hartley J, Knapp GC 4th, Cheng W, Jiang MS, Roach JM, Yang X, Giardina SL, Mitra G, Yovandich JL, Creekmore SP, Waldmann TA, Zhu J.Biotechnol Prog.

5. Characterization of recombinant human IL-15 deamidation and its practical elimination through substitution of asparagine 77.Nellis DF, Michiel DF, Jiang MS, Esposito D, Davis R, Jiang H, Korrell A, Knapp GC 4th, Lucernoni LE, Nelson RE, Pritt EM, Procter LV, Rogers M, Sumpter TL, Vyas VV, Waybright TJ, Yang X, Zheng AM, Yovandich JL, Gilly JA, Mitra G, Zhu J.Pharm Res.

6. Activated expression of the chemokine Mig following chemotherapy contributes to chemotherapy - induced bone marrow suppression and lethal toxicity.Lu H, Zhu S, Qian L, Xiang D, Zhang W, Nie A, Gao J, Wu M, Wang Y, Gao J, Lu B, ,Yu Y, Han W, Moldenhauer A.Blood.

7. Expression and Purification of Recombinant Human Mig in italic Escherichia coli and its bioactivity on human cells and murine model.Qian L, Zhu S, Shen J, Han X Gao J, Wu M, Lu H*, Han W.Protein Expr Purif.

8. Prokaryotic expression and purification of murine monokine induced by IFN-γ.Lu H, Yu M, Sun Y, Mao W, Wang Q, Wu M, Han W.Protein Expr Purif.

9. Interleukin 32 promotes hematopoietic progenitor expansion and attenuates bone marrow cytotoxicity.Moldenhauer A, Futschik M, Lu H, Helmig M, G?tze P, Bal G, Zenke M, Han W, Salama A.Eur J Immunol.

10. Zebrafish complement factor H and its related genes: identification, evolution, and expression.Sun G, Li H, Wang Y, Zhang B, Zhang S.Funct Integr Genomics.

11. Effects of extremely low frequency magnetic field on growth and differentiation of human mesenchymal stem cells.Yan J, Dong L, Zhang B, Qi N.Electromagn Biol Med.

12. Biocompatibility Evaluation of Chitosan-based Injectable Hydrogels for the Culturing Mice Mesenchymal Stem Cells in vitro.Yan J, Yang L, Wang G, Xiao Y, Zhang B, Qi N.J Biomater Appl.